Finlay Institute

Covid-19 development round-up: December 9, 2021

The state of the fight: 

New studies supported heterologous primary regimens and heterologous boosters.
  Serum Institute of India is weighing slashing Covishield production by 50%.
  The U.S. FDA OK’d AstraZeneca’s Evusheld long-acting monoclonal antibody therapy as PrEP for certain groups.

 

AUTHORIZED VACCINES  

Mixing the AstraZeneca/Oxford or Pfizer/BioNTech vaccines with a second dose of Moderna’s shot generated non-inferior immune responses…

Mentions:
Covid-19, vaccines, drugs, AstraZeneca, Pfizer, BioNTech, Moderna, Novavax, Finlay Institute, Gamaleya Institute, CureVac, J&J, Janssen, Valneva, EMA, Bavarian Nordic, Sinovac, CEPI, SII, Gavi, COVAX, Africa CDC, WHO, World Bank, UNICEF, Zydus Cadila, Thermo Fisher, Merck, FDA, GSK
Read more
Covid-19 development round-up: December 3, 2021

The state of the fight: 

A slew of vaccine manufacturers announced plans to tackle the Omicron variant.
  Aspen Pharmacare and J&J neared a deal that would let the South African manufacturer market its own version of the Janssen shot.
  Gavi’s board approved the alliance’s COVAX strategy for 2022.

AUTHORIZED VACCINES  


New research on the Pfizer/BioNTech shot affirmed its efficacy in younger people and its safety in older people.
 
…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, BBIL, FDA, Moderna, Gamaleya Institute, AstraZeneca, CNBG, Sinopharm, J&J, Janssen, Sinovac, Valneva, CEPI, Finlay Institute, Inovio, Novavax, WHO, EMA, Walvax, CureVac, Gavi, COVAX, MPP, Africa CDC, Merck, Lilly, Regeneron, Roche, GSK, Vir, Pfizer
Read more
Covid-19 development round-up: November 12, 2021

The state of the fight: 

More European countries cautioned against Moderna’s vaccine for younger people over concerns about side effects.
  Generics companies are preparing to roll out their versions of Merck’s molnupiravir oral antiviral.
  Pfizer is in talks with 90 countries over supply deals for its antiviral candidate.

 

AUTHORIZED VACCINES  


France and Germany recommended against the Moderna vaccine for people under 30 over concerns…

Mentions:
Covid-19, vaccines, drugs, Moderna, Pfizer, BioNTech, BBIL, WHO, AstraZeneca, CanSino, Finlay Institute, CNBG, Sinopharm, Sinovac, Walvax, Inovio, Valneva, Zydus Cadila, ACT-A, BMGF, COVAX, J&J, Janssen, EuBiologics, Merck, MPP, EMA, Regeneron, Roche
Read more
Covid-19 development round-up: September 17, 2021

The state of the fight: 

A U.S. regulatory committee endorsed booster doses for vulnerable people and those over age 65.
  Kenya outlined plans to start fill-finish production of Covid-19 shots in early 2022.
  An SII subsidiary scooped up a 15% stake in Biocon’s biologics unit as the companies launched a strategic alliance to produce and commercialize vaccines. Approved or authorized vaccines

 
A new substudy in The Lancet supports flexible schedules for…

Mentions:
Covid-19, vaccines, drugs, AstraZeneca, EMA, Pfizer, BioNTech, Moderna, Novavax, Gamaleya Institute, CNBG, Sinopharm, J&J, Janssen, BioCubaFarma, Finlay Institute, FDA, WHO, SII, Bio E, Valneva, CureVac, Sinovac, Walvax, Biocon, Lilly, Regeneron, Roche, Gilead
Read more
Covid-19 development round-up: March 26, 2021

The state of the hunt:

The European Union and India made new moves to curtail vaccine exports.
  COVAX warned of delivery delays.
  Pfizer and BioNTech launched a pediatric trial of their vaccine in children as young as 6 months.

 

Vaccines


Approved or authorized vaccines
   
New data, new questions for AstraZeneca: If AstraZeneca thought higher-than-expected efficacy results this week from the U.S.-based Phase 3 trial of AZD1222…

Mentions:
Covid-19, vaccines, drugs, AstraZeneca, NIAID, SII, Pfizer, BioNTech, Gamaleya Institute, Sinovac, CanSino, J&J, Janssen, CureVac, Clover Biopharmaceuticals, Dynavax, Daiichi Sankyo, Butantan Institute, University of Sao Paulo Ribeirão Preto, Farmacore, PDS Biotechnology, EC, COVAX, COVAX AMC, EMA, Halix, Oxford University, AU, CNBG, Sinopharm, Drugmex, Virchow Biotech, RDIF, Gland Pharma, Hetero Biopharma, Stelis Biopharma, Torlak Institute, Catalent, FDA, Novavax, Moderna, Pharmaniaga, UNICEF, Corning, Gavi, COVAX Buffer, COVAX Facility, WHO, Finlay Institute, MSF, VMIC, Regeneron, Lilly, Zydus Cadila, Gilead, Celltrion, ChemRar Group, GSK, Vir, RedHill Biopharma, MGC Pharma, AptaBio, Omeros, Quantum Leap Healthcare Collaborative, Vasomune
Read more
Covid-19 development round-up: March 4, 2021

The state of the hunt:

Serum Institute of India will export Covishield doses to the United Kingdom.
  COVAX unveiled initial vaccine allocations, and numerous COVAX participants received their first shipments and began administering jabs.
  Bharat Biotech’s Covaxin demonstrated 81% efficacy against symptomatic disease in an interim Phase 3 analysis.

 

Vaccines


Approved or authorized vaccines
  
U.S. regulators completed their…

Mentions:
Covid-19, vaccines, drugs, diagnostics, COVAX, Merck, J&J, Janssen, Novartis, CureVac, BBIL, FDA, EUAs, CDC, EMA, AstraZeneca, Oxford University, IMCAS, Anhui Zhifei Longcom, Moderna, Health Canada, Takeda, Sinovac, Gamaleya Institute, Pfizer, BioNTech, CNBG, Sinopharm, Novavax, Finlay Institute, Inovio, BARDA, Catalent, SII, Verity Pharmaceuticals, World Bank, JCR Pharma, IBM, GC Pharma, Mabion, EuBiologics, LG Chem, Glovax Biotech, Gavi, UNOPS, WHO, BIBP, Access Consortium, EC, Celltrion, NIH, GSK, Vir, Brii Biosciences, Veru, Apellis, Cepheid, Quidel
Read more
Covid-19 development round-up: February 19, 2021

The state of the hunt:

Two versions of the AstraZeneca/Oxford vaccine secured EUL from the World Health Organization.
  J&J has applied for both WHO and EMA authorization for Janssen’s Covid-19 vaccine.
  The Pfizer/BioNTech shot remains stable at higher temperatures than previously believed.

 

Vaccines


Approved or authorized vaccines
 
Pfizer and BioNTech are testing their vaccine in pregnant women through a 4,000-…

Mentions:
Covid-19, vaccines, drugs, AstraZeneca, Oxford University, EUL, WHO, J&J, Janssen, EMA, Pfizer, BioNTech, SK Bioscience, SII, COVAX, R-Pharm, FDA, Sinovac, Bio Farma, BBIL, Dr. Reddy’s Laboratories, RDIF, CNBG, Sinopharm, BIBP, Finlay Institute, Altimmune, ReiThera, Leukocare, Univercells, AU, Africa CDC, State Pharmaceutical Corporation, Novavax, Gamaleya Institute, Moderna, EC, Butantan Institute, IMCAS, Anhui Zhifei Longcom, Bayer, CureVac, COVAX AMC, Gavi, UNSC, Renergen, MTN Group, NIH, Gilead, Lilly, Fujifilm Toyama, RedHill Biopharma, Kalbe Farma, Kalbe Genexine Biologics, Genexine, CMTx Biotech
Read more
Covid-19 development round-up: January 15, 2021

The state of the hunt:

India inked vaccine supply deals with Bharat Biotech and SII.
  BioNTech upped its 2021 production target for Comirnaty to 2 billion doses—but the Pfizer/BioNTech vaccine faced near-term production slowdowns and delivery lags.
  An African Union-backed supply initiative locked up 270 million vaccine doses for the continent.

 

Vaccines


Approved or authorized vaccines

Sinovac’s inactivated jab notched its…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Sinovac, Butantan Institute, Lekhim, Moderna, Gamaleya Institute, Pfizer, BioNTech, BBIL, AstraZeneca, Janssen, J&J, IMCAS, Finlay Institute, Pasteur Institute, ExpreS2ion Biotech, SII, Oxford, Beximco Pharmaceuticals, Novavax, Precisa Medicamentos, EMA, Pharmaniaga, African Union, Afreximbank, Baxter Biopharma Solutions, Valneva, EU, CNBG, Sinopharm, WHO, COVAX AMC, COVAX, Gavi, halal, Regeneron, Lilly, BARDA, Gilead, Relief Therapeutics, Innovation Pharmaceuticals, FDA, NeuroRx, Alexion, Celltrion, Synairgen, GSK, Vir, Relay Medical, DiaSorin
Read more
Covid-19 development round-up: October 9, 2020

The state of the hunt:

China will join the COVAX Facility, its foreign ministry announced Thursday.
  Regeneron requested U.S. FDA emergency authorization for a monoclonal antibody cocktail, and Eli Lilly planned a similar request for its mAb cocktail in November. 
  Remdesivir showed expanded benefits in final Phase 3 results published in the New England Journal of Medicine.

 

Vaccines

Phase 3 candidates:
 
The European Medicines…

Mentions:
Covid-19, vaccines, drugs, diagnostics, COVAX Facility, Lilly, Regeneron, FDA, EMA, Pfizer, BioNTech, AstraZeneca, Moderna, Fiocruz, Dr. Reddy’s, Finlay Institute, ViroVax, Technovalia, BioNet, PharmaJet, CAMS, Kindred Biosciences, Vaxart, Recipharm, Arcturus, J&J, Janssen, Rentschler Biopharma, HDT Bio, NIAID, Shenzhen Genius Biotech, Gavi, COVAX AMC, WHO, Gilead, BMGF, COVID-19 Therapeutics Accelerator, Fujifilm Diosynth, AbCellera, Junshi, CSL Behring, Emergent BioSolutions, Grifols, Takeda, Vir Biotechnology, ARCA Biopharma, Atea Pharmaceuticals, TLC, Noxopharm, Caladrius Biosciences, Revelation Biosciences, Fosun, Sorrento, ViralClear, BioSig, NIMR, Beckman Coulter, BARDA, Cepheid, Quidel, NIH, RADx, Dascena, Abbott, WTO, USAID, Tufts, NCI, SeroNet, Fred Hutchinson
Read more
Covid-19 development round-up: August 28, 2020

The state of the hunt:

Novavax brought its vaccine candidate to Phase 2.
  WHO reportedly offered wealthier countries new, more flexible terms for the COVAX Facility.
  The U.S. FDA expanded the Emergency Use Authorization for Gilead’s Veklury (remdesivir).

 

Vaccines

Phase 3 candidates:
 
Pfizer and BioNTech have enrolled more than half of the 30,000 people they seek for U.S.-based Phase 3 trials of their mRNA Covid-19 vaccine…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Novavax, WHO, COVAX, FDA, Gilead, Pfizer, BioNTech, Moderna, J&J, CNBG, Sinovac, RDIF, SK-Pharmacy, CanSino, SII, AstraZeneca, ReiThera, Sanofi, Adimmune, Finlay Institute, BioCubaPharma, BBIL, Bharat Biotech, Bio Farma, Pharmaniaga, Takeda, Jacobson Pharma, Fosun, Beximco, CEPI, Biovac, Catalent, Arcturus, Ology, ATCC, West China Hospital, WUSTL, Vaccitech, Eijkman, Translate Bio, VBI Vaccines, Scancell, DIOSynVax, Altimmune, Gavi, COVAX AMC, BARDA, Esperovax, Vaxess, Verndari, Panacea, Refana, Hetero, VUMC, NIH, HiFiBio, Asalyxa, Cynata, Laurent, Pluristem, Capricor, Mereo, Celltrion, BeiGene, Singlomics, Sorrento, AbbVie, Abbott, QIAGEN, SCORE, KT, RIGHT Fund, J&J Innovations
Read more
Subscribe to Finlay Institute